Background
The persistence of HIV reservoirs in T cells and myeloid cells precludes HIV cure. Some broadly neutralising anti-HIV envelope (Env) antibodies (bNAbs) can bind HIV-infected cells and elicit natural killer (NK) cell antibody-dependent cellular cytotoxicity (ADCC). Removal of core fucose from the Fc region of antibodies can increase NK cell ADCC, but remains to be fully explored in HIV. The aim of this study was to examine the utility of afucosylated bNAbs to enhance ADCC of multiple HIV-infected cell types by NK cells.
Methods
A panel of seven bNAbs were generated in the presence or absence of a fructosyltransferase inhibitor (2F-Peracetyl-Fucose) and purified using protein-G chromatography. Opsonisation of cell-surface Env on primary CD4+ T cells and monocyte-derived macrophages (MDM) infected with HIVBaL in vitro was evaluated by immunolabeling. NK cell ADCC responses to HIV Env-expressing targets in the presence of 5µg/mL of bNAbs was assessed via flow cytometry using a CD107a degranulation assay. Elimination of 8E5 cells was assessed as loss of HIV-expressing (p24+) cells after incubation with NK cells +/- unmodified and afucosylated bNAbs.
Results
The bNAbs NIH45-46, VRC01, CH103, PGT151 and 35O22 were able to bind Env expressed on the surface of all HIV-expressing cells including macrophages. 8ANC195 had limited ability to opsonise HIV-infected cells, while PGT135 non-specifically opsonised HIV-uninfected MDM. Afucosylated bNAbs demonstrated a significant reduction in core fucosylation compared to unmodified bNAbs (range 31.6 to 38.6% reduction). Afucosylated bNAbs significantly increased ADCC responses from NK cells in response to CD4+ T cells (average 2.1 fold-increase, p<0.05 for all) and MDM (2.6-fold increase, p<0.02 for all) when compared to unmodified bNAbs. A combination of afucosylated NIH45-46, CH103 and 35O22 induced a significant increase in the proportion of non-viable HIV-expressing 8E5 target cells following incubation with either peripheral blood mononuclear cell (2.4-fold increase, p=0.002) or NK cell (1.7-fold increase, p=0.02) effectors.
Conclusions
We have identified a panel of anti-Env bNAbs that opsonise HIV-infected CD4+ T cells and macrophages, and show proof of principle that afucosylation modifications of bNAbs can enhance NK cell mediated ADCC in vitro. Together, these findings support the use of anti-Env bNAbs with reduced core fucosylation as a promising immunotherapy tool to achieve ART-free HIV control.
Table or Figure
![]()